MedTrace Logo

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-04-15

No results posted yet for this study

Summary

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).

Conditions

Interventions

DRUG

Tislelizumab

Administered by intravenous infusion

DRUG

BGB-A445

Administered by intravenous infusion

DRUG

LBL-007

Administered by intravenous infusion

DRUG

Carboplatin

Investigator's choice; administered by intravenous infusion

DRUG

Cisplatin

Investigator's choice; administered by intravenous infusion

DRUG

pemetrexed

Investigator's choice; administered by intravenous infusion

DRUG

Paclitaxel

Investigator's choice; administered by intravenous infusion

DRUG

Nab paclitaxel

Investigator's choice; administered by intravenous infusion

DRUG

BGB-15025

Administered Orally

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-07
Primary Completion
2025-12-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • China
  • France
  • Georgia
  • Italy
  • Malaysia
  • Moldova
  • Romania
  • Singapore
  • South Korea
  • Spain
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05635708 on ClinicalTrials.gov